Bone turnover biomarkers in COPD patients randomized to either a regular or shortened course of corticosteroids: a substudy of the randomized controlled CORTICO-COP trial

• Published in: Respiratory Research 2020, Vol.21 (1)
• Main Authors: Sivapalan, Pradeesh, Jargensen, Niklas R, Mathioudakis, Alexander G, Eklöf, Josefin, Lapperre, Therese, Ulrik, Charlotte Suppli, Andreassen, Helle F, Armbruster, Karin, Sivapalan, Praleene, Janner, Julie, Godtfredsen, Nina, Weinreich, Ulla M, Nielsen, Thyge L, Seersholm, Niels, Wilcke, Torgny, Schuetz, Philipp, Klausen, Tobias W, Marså, Kristoffer, Vestbo, Jargen, Jensen, Jens-Ulrik
• Format: Report
• Language: English
• Subjects: Bone resorption; Causes of; Chronic obstructive lung disease; Complications and side effects; Corticosteroid drugs; Dosage and administration; Drug therapy
• ISSN: 1465-9921
• DOI: 10.1186/s12931-020-01531-9

Background Long-term treatment with corticosteroids causes loss of bone density, but the effects of using short-term high-dose systemic-corticosteroid therapy to treat acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are unclear. Our aim was to determine whether high-dose corticosteroid therapy affected bone turnover markers (BTMs) to a greater extent compared to low-dose corticosteroid therapy. Methods The CORTICO-COP trial (NCT02857842) showed that an eosinophil-guided corticosteroid intervention led to approximately 60% lower accumulated corticosteroid dose for hospitalized patients with AECOPD (low-dose group) compared with 5-day standard corticosteroid treatment (high-dose group). We compared the levels of BTMs C-terminal telopeptide of type 1 collagen (CTX) and procollagen type 1 N-terminal propeptide (P1NP) in 318 participants during AECOPD and at 1- and 3-month follow-up visits. Results CTX decreased and P1NP increased significantly over time in both treatment groups. There were no significant differences between the groups at 1- or 3-months follow-up for P1NP. A significant drop in CTX was seen at 3 months (down [DELA]24% from the baseline, p = 0.017) for the high dose group. Conclusion Short-term, high-dose systemic corticosteroid treatment caused a rapid suppression of biomarkers of bone resorption. Corticosteroids did not suppress biomarkers of bone formation, regardless of patients receiving low or high doses of corticosteroids. This therapy was, therefore, harmless in terms of bone safety, in our prospective series of COPD patients. Trial registration ClinicalTrials.gov Identifier: NCT02857842. Submitted August 2nd, 2016. Keywords: Adverse effects, Bone remodelling, Bone turnover markers, Chronic obstructive pulmonary disease, Corticosteroids